HER2 positive or HER2-low metastatic breast cancer research hub

An Open-label, Multicenter, Phase 2 Dose Optimization and Expansion Study to Evaluate the Safety and Efficacy of BB-1701, an anti-human epidermal growth factor receptor 2 (anti-HER2) antibody-drug conjugate (ADC), in Previously Treated Subjects with HER2-positive or HER2-low Unresectable or Metastatic Breast Cancer

This study looks at a new drug, BB-1701, for advanced breast cancer that has HER2 markers. It aims to find the best dose and check how safe and effective it is for patients who've already had treatment.